Literature DB >> 18722675

The myasthenia gravis thymus: a rare source of human autoantibody-secreting plasma cells for testing potential therapeutics.

Marguerite E Hill1, Hiroyuki Shiono, John Newsom-Davis, Nick Willcox.   

Abstract

In early-onset myasthenia gravis (EOMG), the thymus is colonized by lymph node-like infiltrates including T cell areas and germinal centers. Our Group(1) showed (1978) spontaneous anti-acetylcholine receptor (AChR) autoantibody production by EOMG thymic cells. Especially after enzymic dispersal, these are enriched in plasma cells that are evidently autonomous, long-lived, terminally differentiated and radio-resistant. Radiolabeled AChR is highly sensitive both for localizing them in situ and detecting their ongoing antibody production in culture at limiting cell numbers. Thus EOMG thymi are a readily available source of specific autoimmune human plasma cells suitable for studying their biology and testing new therapies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18722675     DOI: 10.1016/j.jneuroim.2008.06.027

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  17 in total

1.  Dysregulation of B Cell Repertoire Formation in Myasthenia Gravis Patients Revealed through Deep Sequencing.

Authors:  Jason A Vander Heiden; Panos Stathopoulos; Julian Q Zhou; Luan Chen; Tamara J Gilbert; Christopher R Bolen; Richard J Barohn; Mazen M Dimachkie; Emma Ciafaloni; Teresa J Broering; Francois Vigneault; Richard J Nowak; Steven H Kleinstein; Kevin C O'Connor
Journal:  J Immunol       Date:  2017-01-13       Impact factor: 5.422

Review 2.  B cells in the pathophysiology of myasthenia gravis.

Authors:  John S Yi; Jeffrey T Guptill; Panos Stathopoulos; Richard J Nowak; Kevin C O'Connor
Journal:  Muscle Nerve       Date:  2017-09-30       Impact factor: 3.217

3.  Local renal autoantibody production in lupus nephritis.

Authors:  Marion Espeli; Susanne Bökers; Giovanna Giannico; Harriet A Dickinson; Victoria Bardsley; Agnes B Fogo; Kenneth G C Smith
Journal:  J Am Soc Nephrol       Date:  2010-11-18       Impact factor: 10.121

Review 4.  Spontaneous germinal centers and autoimmunity.

Authors:  Phillip P Domeier; Stephanie L Schell; Ziaur S M Rahman
Journal:  Autoimmunity       Date:  2017-02       Impact factor: 2.815

Review 5.  Novel pathophysiological insights in autoimmune myasthenia gravis.

Authors:  Gianvito Masi; Kevin C O'Connor
Journal:  Curr Opin Neurol       Date:  2022-08-04       Impact factor: 6.283

Review 6.  Thymus, thymoma and myasthenia gravis.

Authors:  Yoshitaka Fujii
Journal:  Surg Today       Date:  2012-09-05       Impact factor: 2.549

Review 7.  Bortezomib: a proteasome inhibitor for the treatment of autoimmune diseases.

Authors:  Naeemeh Khalesi; Shahla Korani; Mitra Korani; Thomas P Johnston; Amirhossein Sahebkar
Journal:  Inflammopharmacology       Date:  2021-08-23       Impact factor: 4.473

8.  Inflammation and epstein-barr virus infection are common features of myasthenia gravis thymus: possible roles in pathogenesis.

Authors:  Paola Cavalcante; Lorenzo Maggi; Lara Colleoni; Rosa Caldara; Teresio Motta; Carmelo Giardina; Carlo Antozzi; Sonia Berrih-Aknin; Pia Bernasconi; Renato Mantegazza
Journal:  Autoimmune Dis       Date:  2011-09-26

9.  Proteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patients.

Authors:  Nick Willcox; Pilar Martinez-Martinez; Mario Losen; Alejandro M Gomez; Kathleen Vrolix; Jonas Hummel; Gisela Nogales-Gadea; Abhishek Saxena; Hans Duimel; Fons Verheyen; Peter C Molenaar; Wim A Buurman; Marc H De Baets
Journal:  J Immunol       Date:  2014-06-27       Impact factor: 5.422

Review 10.  Ectopic lymphoid-like structures in infection, cancer and autoimmunity.

Authors:  Costantino Pitzalis; Gareth W Jones; Michele Bombardieri; Simon A Jones
Journal:  Nat Rev Immunol       Date:  2014-06-20       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.